Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug445 | Biological data Wiki | 0.41 |
| drug784 | Clinical data Wiki | 0.33 |
| drug2884 | Robot Assisted Percutaneous Cardiovascular Intervention Wiki | 0.29 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1312 | Filtration Test Wiki | 0.29 |
| drug3775 | cardiac magnetic resonance Wiki | 0.29 |
| drug4136 | viral sequence Wiki | 0.29 |
| drug2444 | Percutaneous Coronary Revascularization for STEMI Wiki | 0.29 |
| drug1301 | Favipiravir and Hydroxychloroquine Wiki | 0.29 |
| drug3988 | oropharyngeal and intestinal microbiota Wiki | 0.29 |
| drug1316 | Fit test Wiki | 0.29 |
| drug3727 | albuterol sulfate (nebulizer) Wiki | 0.29 |
| drug319 | Attention control Wiki | 0.29 |
| drug3333 | Tele-medicine platform Wiki | 0.29 |
| drug24 | 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse Wiki | 0.29 |
| drug3240 | Storage of operating waste Wiki | 0.29 |
| drug3726 | albuterol sulfate (MDI) Wiki | 0.29 |
| drug3867 | host immune factors Wiki | 0.29 |
| drug2086 | Motivational social support from nurse with additional support from significant other Wiki | 0.29 |
| drug3866 | host genotype Wiki | 0.29 |
| drug2085 | Motivational social support from nurse Wiki | 0.29 |
| drug58 | 50 mg/mL Virazole Wiki | 0.20 |
| drug25 | 100 mg/mL Virazole Wiki | 0.20 |
| drug2215 | No intervention Wiki | 0.06 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D009203 | Myocardial Ischemia NIH | 1.00 |
| D007238 | Infarction NIH | 0.82 |
| D003324 | Coronary Artery Disease NIH | 0.43 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000787 | Angina Pectoris NIH | 0.29 |
| D054058 | Acute Coronary Syndrome NIH | 0.29 |
| D003327 | Coronary Disease NIH | 0.29 |
| D054143 | Heart Failure, Systolic NIH | 0.29 |
| D016757 | Death, Sudden, Cardiac NIH | 0.29 |
| D013610 | Tachycardia NIH | 0.29 |
| D017180 | Tachycardia, Ventricular NIH | 0.29 |
| D009205 | Myocarditis NIH | 0.20 |
| D000072657 | ST Elevation Myocardial Infarction NIH | 0.20 |
| D020521 | Stroke NIH | 0.15 |
| D011655 | Pulmonary Embolism NIH | 0.15 |
| D003643 | Death, NIH | 0.14 |
| D004617 | Embolism NIH | 0.14 |
| D016769 | Embolism and Thrombosis NIH | 0.14 |
| D013927 | Thrombosis NIH | 0.11 |
| D006331 | Heart Diseases NIH | 0.11 |
| D054556 | Venous Thromboembolism NIH | 0.10 |
| D006333 | Heart Failure NIH | 0.10 |
| D020246 | Venous Thrombosis NIH | 0.09 |
| D013923 | Thromboembolism NIH | 0.07 |
| D004194 | Disease NIH | 0.06 |
| D002318 | Cardiovascular Diseases NIH | 0.05 |
| D013577 | Syndrome NIH | 0.03 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001677 | Coronary artery atherosclerosis HPO | 0.43 |
| HP:0001649 | Tachycardia HPO | 0.29 |
| HP:0001681 | Angina pectoris HPO | 0.29 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0004756 | Ventricular tachycardia HPO | 0.29 |
| HP:0001645 | Sudden cardiac death HPO | 0.29 |
| HP:0012819 | Myocarditis HPO | 0.20 |
| HP:0001297 | Stroke HPO | 0.15 |
| HP:0002204 | Pulmonary embolism HPO | 0.15 |
| HP:0001907 | Thromboembolism HPO | 0.12 |
| HP:0001635 | Congestive heart failure HPO | 0.10 |
| HP:0002625 | Deep venous thrombosis HPO | 0.09 |
| HP:0001626 | Abnormality of the cardiovascular system HPO | 0.05 |
Navigate: Correlations HPO
There are 12 clinical trials
After a 30-year decline, heart disease is projected to increase up to 18% by 2030. Participation rates in cardiac rehabilitation remain extremely low and hopeless individuals are less likely to participate. This innovative study has the potential to advance science, improve patient care, and improve patient outcomes by demonstrating the effectiveness of the Heart Up! program to increase physical activity and reduce hopelessness in patients with heart disease. Hopelessness is associated with a 3.4 times increased risk of mortality or nonfatal myocardial infarction in patients with ischemic heart disease (IHD), independent of depression. Hopelessness has been identified in 27-52% of patients with IHD and can persist for up to 12 months after hospital discharge. Hopelessness, a negative outlook and sense of helplessness toward the future, can be a temporary response to an event (state) or a habitual outlook (trait). Hopelessness is associated with decreased physical functioning and lower physical activity (PA) levels in individuals with IHD. While research has investigated strategies to increase PA among IHD patients in general, the study team is the only group to design an intervention to promote PA specifically in hopeless IHD patients. The purpose of this randomized controlled trial is to establish the effectiveness of our 6-week mHealth intervention (Heart Up!) to promote increased PA in hopeless patients with IHD. A total of 225 hopeless IHD patients will be enrolled from a large community teaching hospital in the Midwest. Patients will be randomized (75 per group) to one of three groups: 1) motivational social support (MSS) from a nurse, 2) MSS from a nurse with additional significant other support (SOS), or 3) attention control (AC). It is hypothesized that 1) The MSS with SOS group will have the greatest increase in average minutes of moderate to vigorous PA per day at 8 and 24 weeks as compared to the MSS only or AC groups; 2) Greater increase in minutes of moderate to vigorous PA per day will be associated with decreased state hopelessness levels from baseline to weeks 8 and 24; and 3) Increased social support and increased motivation will mediate the effects of Heart Up! on a greater increase in moderate to vigorous PA at 8 and 24 weeks. The findings from this study could transform care for IHD patients who are hopeless by promoting self-management of important PA goals that can contribute to better health outcomes.
Description: Mean minutes/day moderate to vigorous physical activity
Measure: ActiGraph GT9X Link Accelerometer Time: Month 12Description: Participant's report of current level of state hopelessness. Total score range= 1 (better) to 4 (worse).
Measure: State-Trait Hopelessness Scale Time: Month 12Description: Participant's report of exercise self-regulation level. Total score range= 1 (worse) to 7 (better).
Measure: Exercise Self-Regulation Questionnaire Time: Month 12Description: Participant's report of perceived social support level. Total score range= 1 (worse) to 30 (better).
Measure: ENRICHD Social Support Inventory Time: Month 12Description: Comorbidity score based on medical record abstraction. Total score range= 0 (better) to 100 (worse).
Measure: Charlson Comorbidity Index Time: Week 1Description: Participant's report of participation level with exercise in home, community or cardiac rehabilitation program
Measure: Cardiac Rehabilitation Exercise Participation Tool Time: Month 12Description: Participant's report of mean level of depressive symptoms. Total score range= 0 (better) to 27 (worse).
Measure: Patient Health Questionnaire-9 Time: Month 12Description: Participant's report of mean level of well-being. Total score range= 4 (better) to 20 (worse).
Measure: PROMIS-29 Time: Month 12Description: Participant's report of mean level state and trait hope. Total score range= 8 (worse) to 64 (better).
Measure: Snyder State Trait Scales Time: Month 12Description: Participant's report of mean level of quality of life. Total score range= 1 (better) to 5 (worse).
Measure: EuroQol (EQ-5d-5L) Time: Month 12Description: Participant's report of COVID-19 symptoms, diagnosis, testing, and social distancing. No score range (14 items).
Measure: Multi-Ethnic Study of Atherosclerosis (MESA) COVID-19 Questionnaire Time: Month 12Description: Participant's report of impact on routine; income/ employment; access to food, medical and mental health care, extended family; and stress. No range (12 items)
Measure: Coronavirus Impact Scale Time: Month 12Management of known patients with cardiovascular disease (in particular the whole spectrum of atherosclerotic ischaemic coronary artery disease, essential hypertension under treatment, and also patients with chronic heart failure under medication) and with other associated chronic pathologies, with obvious effects on the management of the pandemic with modern / distance means (e-Health) of patients at high risk of mortality in contact with coronavirus. Given the Covid-19 Pandemic, all the above complex cardiovascular patients are under the obligation to stay in the house isolated and can no longer come to standard clinical and paraclinical monitoring and control visits. Therefore, a remote management solution (tele-medicine) of these patients must be found. The Investigators endeavour is to create an electronic platform to communicate with these patients and offer solutions for their cardiovascular health issues (including psychological and religious problems due to isolation). The Investigators intend to create this platform for communicating with a patient and stratify their complaints in risk levels. A given specialist will sort and classify their needs on a scale, based on specific algorithms (derived from the clinical European Cardiovascular Guidelines), and generate specific protocols varying from 911 like emergencies to cardiological advices or psychological sessions. These could include medication changing of doses, dietary advices or exercise restrictions. Moreover, in those patients suspected of COVID infection, special assistance should be provided per protocol.
Description: Development of an electronic (e-HEALTH) framework structure for management of patients with known cardiovascular disease in COVID19 pandemic social context
Measure: Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients Time: 6 monthsDescription: patients come into direct contact with the case coordinator, who provides ongoing assistance, including for connecting to devices that ensure real-time data transmission and directing to specialist teams that establish stage diagnosis and management / therapy behavior (including adjustment). doses, decisions to discontinue medication or to add medication);
Measure: Number of patients included in this platform Time: 6 monthsDescription: Will be the number of sessions per patient multiplied with the number of patients included
Measure: Number of consultations/sessions given Time: 6 monthsPatients with COVID-19 in the Intensive Care Unit (ICU) or hospitalized with severe form have a poor prognosis (almost 30% rate of death). They present often a high cardiovascular risk profile (almost 30% of hypertension and 19% of diabetes). Troponin has been described to be elevated in a high proportion of patients (one fifth of all patients and 50% of non-survivors) suggesting the possibility of cardiomyopathies. High levels of DDimers (81% of non survivors) and fibrin degradation products are also associated with increased risk of mortality suggesting also the possibility of venous thromboembolism. Therefore, screening for cardiomyopathies and venous thromboembolism could represent an important challenge for patients with COVID-19 management.
Description: Incidence of cardiomyopathies and/or venous thromboembolism at day 28
Measure: Determine the incidence of cardiomyopathies and venous thromboembolism Time: 28 daysDescription: Incidence of mortality at day 28
Measure: Mortality Time: 28 daysDescription: Number of day of using mechanical ventilation for each patients
Measure: Duration of mechanical ventilation Time: hospitalisation durationDescription: Incidence of shock during hospitalisation
Measure: Shock Time: hospitalisation durationDescription: Number of day at hospital
Measure: length of stay Time: hospitalisation durationDescription: Setting up or not of mechanical ventilation
Measure: Mechanical ventilation Time: hospitalisation durationDescription: Administration or not of renal replacement therapy
Measure: Renal replacement therapy Time: hospitalisation durationIn late December 2019, an emerging disease due to a novel coronavirus (named SARS-CoV-2) rapidly spread in China and outside. France is currently facing the COVID-19 wave with more than 131 863 confirmed cases and almost 25 201 deaths. Systems of care have been reorganized in an effort to preserve hospital bed capacity, resources, and avoid exposure of patients to the hospital environment where COVID-19 may be more prevalent. Therefore, elective procedures of catheterization and programmed hospitalizations have been delayed. However, a significant proportion of procedures within the catheterization laboratory such as ST-elevation myocardial infarction (STEMI), non ST elevation myocardial infarction or unstable angina are mandatory and cannot be postponed. Surprisingly, invasive cardiologist noticed a drop in STEMI volume without reliable data to confirm this impression. Furthermore, a recent single center report in Hong Kong pointed out longer delays of taking care when compared to patients with STEMI treated with percutaneous intervention the previous year. These data are at major concern because delay in seeking care or not seeking care could have detrimental impact on outcomes.
Description: Free wall rupture, acute ischemic mitral regurgitation, ventricular septal rupture
Measure: The primary endpoint is a composite of death from all causes and mechanical complications of acute myocardial infarction (MI) Time: 3 months (between March 1 to May 31, 2019 and between March 1 to May 31, 2020 )Description: Compare the number of patients presenting to cardiology department with acute myocardial infarction in 2019 versus in 2020
Measure: Rates of patients presenting with acute myocardial infarction Time: 3 months (between March 1 to May 31, 2019 and between March 1 to May 31, 2020 )Description: Correlation between clinical patient profile and the degree of affection of regions by COVID-19
Measure: Patient profile during admission for acute myocardial infarction Time: 3 months (between March 1 to May 31Description: Correlation between the delay between onset of symptoms - first medical contact - coronary angiography room and the degree of affection of regions by COVID-19
Measure: Medical care times analysis Time: 3 months (between March 1 to May 31)Description: Delay in minutes from symptom onset and STEMI (ST Segment Elevation Myocardial Infarction) diagnosis; and delay in minutes from onset of symptoms and primary PCI (percutaneous coronary intervention)
Measure: Medical care times analysis Time: 3 months (between March 1 to May 31, 2019 and between March 1 to May 31, 2020 )Description: Correlation between the fate of patient and the degree of affection of regions by COVID-19: Number of days in cardiology department, Left Ventricular Ejection Fraction at discharge, presence of hemodynamic complications, presence of mechanical complications, transfer to intensive care unit, infection with COVID-19 during hospitalization, living status at discharge
Measure: Clinical evolution of patients Time: 3 months (between March 1 to May 31)Description: Number of in hospital outcomes including orotracheal intubation, cardiogenic shock, arrhythmias (ventricular tachycardia of ventricular fibrillation) and in hospital cardiac arrest
Measure: Clinical evolution of patients Time: 3 months (between March 1 to May 31, 2019 and between March 1 to May 31, 2020 )Description: Number of patient admitted in cardiology department with STEMI (ST Segment Elevation Myocardial Infarction)
Measure: STEMI (ST Segment Elevation Myocardial Infarction) admissions incidence rates Time: 3 months (between March 1 to May 31, 2019 and between March 1 to May 31, 2020 )Description: Correlation between the number of patients who underwent systemic thrombolysis and the degree of affection of regions by COVID-19
Measure: Proportion of patients who underwent systemic thrombolysis Time: 3 months (between March 1 to May 31)Description: Number of patient admitted in cardiology department for acute myocardial infarction infected with COVID-19
Measure: Proportion of patients infected with COVID-19 Time: 3 months (between March 1 to May 31)The current COVID19 pandemic has afflicted almost the whole globe. The stress related to the pandemic, not the direct virus-related injury, can be potentially associated with acute cardiovascular events due to a large list of physical and psychosocial stresses. This study is a cross sectional study that will enroll patients evaluated during the COVID19 pandemic period for acute cardiovascular events.
Description: Acute myocardial infarction as diagnosed by ST segment elevation or depression or inverted T wave on 12-lead EKG and elevated levels of cardiac troponins above the 99% of the normal values. A. Acute MI (STEMI and NSTEMI). B. Aborted on non-aborted sudden cardiac death not attributed to a known etiology. C. Sustained or non-sustained ventricular tachy-arrhythmia not attributed to a known etiology. D. ICD shocks. 3. Absence of suspected or confirmed infection with the COVID19 virus. 4. Definite physical or psycho-social stressful trigger appearing in relation to the COVID-19 situation (lock down stress, financial stress, anger, depression, fear, sorrow, death of a significant person, eating binges, smoking binges, physical stress [carrying walking for shopping and carrying excess weights] ..etc) as judged by a unanimous agreement of three investigators in the steering committee.
Measure: Acute cardiovascular event triggered by COVID-19 stress Time: 4 monthsDescription: Typical ventricular tachycardia on 12-lead EKG or EKG monitor.
Measure: Ventricular tachycardia Time: 4 monthsDescription: acute neurological symptoms of hemiparesis or dysrthria due to brain ischemia proven by computerized tomography or magnatic resonance
Measure: acute stroke Time: 4 monthsDescription: Finding an episode of ventricular tachycardia on interrogation of ICD tracing
Measure: Implantable cardioverter defibrillator (ICD) shock Time: 4 monthsPercutaneous cardiovascular intervention procedures (e.g. coronary angioplasty, peripheral artery angioplasty) must be performed in person, requiring the physical presence of one or more medical, nursing and technical professionals. The control of catheters and interventional materials is performed manually, with the operator positioned next to the patient. This context results in potential for reciprocal exposure to exhaled air, both for the professionals involved and for the patient, with an inherent risk of aerial contamination. It is important to note that interventional procedures are often performed on an urgent or emergency basis (e.g. myocardial infarction), without the possibility of postponement or postponement. The recent robot-assisted cardiovascular intervention makes it possible to modify this scenario by allowing the procedure to be performed effectively and safely in a position far from the patient. In an environment with high potential for contamination, mainly related to the current pandemic caused by the COVID-19 virus, may prove to be a tactic to expand hospital security. It is in this sense that the present pilot proposal is inserted, which, ultimately, aims to evaluate the potential of robotic intervention as a strategy to reduce exposure to exhaled air of patients and professionals during the intervention procedure.
Description: (arterial dilation with residual lesion <50% at angiography and normal anterograde flow)
Measure: Successful cardiovascular intervention Time: Until the end of the procedureThe ISACS STEMI COVID-19 has been established in response to the emerging outbreak of COVID-19 to provide a European overview to estimate the real impact of COVID-19 pandemic on treatment and outcome of STEMI by primary angioplasty, and to identify any potential category of patients at risk for delay to treatment or no presentation.
Description: Number of patients undergoing primary angioplasty
Measure: Number of patients undergoing primary angioplasty Time: March April 2019 and 2020Description: Number of patients undergoing primary angioplasty later 12 hours from symptoms onset;
Measure: Number of patients undergoing primary angioplasty later than 12 hours from symptoms onset; Time: March April 2019 and 2020Description: Number of patients undergoing primary angioplasty later than 30 minutes from PCI hospital admission
Measure: Number of patients undergoing primary angioplasty later than 30 minutes from PCI hospital admission Time: March April 2019 and 2020Description: In-Hospital mortality
Measure: In-hospital mortality Time: March April 2019 and 2020Myocardial injury, as assessed by elevation of cardiac troponins (Tnc), is frequent among patients with COVID-19. Although rare autopsy cases reported COVID-19 related myocardial inflammation, the origin of Tnc elevation is unknown to date. Several cardiac causes, such as myocarditis, non-ischemic myocardial injury (NIMI), or myocardial infarction (MI) may lead to Tnc kinetic. Our work will test the hypothesis that during SARS-Cov2 infection, the elevation of cardiac biomarkers could be linked to the occurrence of myocarditis.
Description: Myocardtitis diagnosis in patients COVID+ and troponin+
Measure: characterize the myocardial damage associated with CoV-2 SARS infection Time: Through study completion, an average of 1 yearThe COVID-19 pandemic highlights the importance of the prognosis of co-morbidities, such as coronary artery disease, which significantly increase the risk of mortality in patients infected with SARS-CoV2. Investigators have recently studied the complex links between respiratory infections, particularly pneumonia, and type 2 myocardial infarction (MI) in many respects. The etiology of type 2 MI is based on an imbalance of myocardial oxygen supply/need in the absence of rupture/erosion of atheromatous plaques. Based on the RICO survey data, the investigators investigated whether COVID-19-related sepsis and/or respiratory failure could be an underlying mechanism of MI2.
Novel coronavirus 2019 (COVID-19) has emerged as a major international public health concern. While much of the morbidity and mortality associated with COVID-19 has been attributed to acute respiratory distress syndrome (ARDS) or end-organ failure, emerging data suggest that disorders of coagulation, in particular hypercoagulability and venous thromboembolism (VTE), may represent an additional major, and possibly preventable, complication (Wu C, et al. JAMA Intern Med. 2020 Mar 13. [Epub ahead of print] and Tang N, et al. Thromb. Haemost. 2020 Feb 19. [EPub Ahead of Print]). Abnormal coagulation testing results, especially markedly elevated D-dimer and FDP, have been associated with a poor prognosis in COVID-19 infection. We propose the following Electronic Health Record (EHR)-guided 10000-patient, retrospective observational cohort study to assess VTE incidence, risk factors, prevention and management patterns, and thrombotic outcomes in patients with COVID-19 infection. In order to gain the valuable perspective of other regional and national centers providing care for large populations of COVID-19, we have started a collaborative network with 5 additional sites which will provide us with de-identified data from 1000 patients each. These 5000 patients in addition to the 5000-patient cohort we are enrolling within the Mass General Brigham Network will comprise this study population.
Description: Frequency (%) of arterial or venous thromboembolism
Measure: Frequency of arterial or venous thromboembolism over 30 days Time: 30 daysDescription: Frequency (%) of arterial or venous thromboembolism
Measure: Frequency of arterial or venous thromboembolism over 90 days Time: 90 daysDescription: Frequency (%) of all-cause death, bleeding, and thromboembolic outcomes
Measure: Frequency of all-cause death, bleeding, and thromboembolic outcomes at 30 days Time: 30 daysDescription: Frequency (%) of all-cause death, bleeding, and thromboembolic outcomes
Measure: Frequency of all-cause death, bleeding, and thromboembolic outcomes at 90 days Time: 90 daysThe COVID-19 pandemic has had dramatic effects on health systems and on non-COVID health care. Using French inpatient claims data and retrospectively collected clinical data, the investigators will assess the changes in hospital admissions for acute cardiovascular and neurovascular conditions in France during and after the national lockdown.
Description: Daily number of admissions for acute cardio- and neurivascular conditions in France.
Measure: Daily number of admissions for acute cardio- and neurivascular conditions in France. Time: 1 dayDescription: Specific mortality rate.
Measure: Specific mortality rate. Time: 1 dayTo compare myocardial injury in COVID 19 patients presented with myocardial infarction and non COVID Patients presented with myocardial infarction evaluated with CMR
Description: Distribution and Extent of myocardial injury in COVID 19 patients presented with myocardial infarction and non COVID Patients presented with myocardial infarction evaluated with CMR.
Measure: comparison between COVID-19 and COVID-19 presented with myocardial infarction Time: baselineAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports